Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 286

Results For "company"

4867 News Found

Alkem to launch novel antibiotic for MDR infections
News | January 31, 2023

Alkem to launch novel antibiotic for MDR infections

Zidavi is recommended by the Infectious Disease Society of America


ExeGi Pharma gets clearance of IND application for EXE-346 a Live biotherapeutic biologic drug
Drug Approval | January 30, 2023

ExeGi Pharma gets clearance of IND application for EXE-346 a Live biotherapeutic biologic drug

This clearance allows the company to initiate a clinical trial for patients with an ileal pouch-anal anastomosis


Briefs: Krsnaa Diagnostics and Solara Active Pharma Sciences
News | January 30, 2023

Briefs: Krsnaa Diagnostics and Solara Active Pharma Sciences

Krsnaa Diagnostics Limited has operationalized one diagnostics center at district hospital Male Akbarpur, Kanpur Dehat, Uttar Pradesh.


Glenmark Life Sciences posts Q3 FY23 PAT at Rs. 104.99 Cr
News | January 29, 2023

Glenmark Life Sciences posts Q3 FY23 PAT at Rs. 104.99 Cr

The company has reported total income of Rs. 547.33 crores during the period ended December 31, 2022


Vimta Labs reports Q3 FY23 consolidated PAT at Rs. 10.24 Cr
News | January 29, 2023

Vimta Labs reports Q3 FY23 consolidated PAT at Rs. 10.24 Cr

The company has reported total income of Rs. 78.50 crores during the period ended December 31, 2022


USFDA provides exception to Glenmark's Baddi facility
Drug Approval | January 28, 2023

USFDA provides exception to Glenmark's Baddi facility

The company will engage with the agency to resolve the import alert at the earliest.


Bliss GVS Pharma posts Q3 FY23 consolidated PAT at Rs. 27.94 Cr
News | January 28, 2023

Bliss GVS Pharma posts Q3 FY23 consolidated PAT at Rs. 27.94 Cr

The company has reported total income of Rs. 211.36 crores during the period ended December 31, 2022


Aarti Drugs Q3 FY23 revenue grows 4%
News | January 28, 2023

Aarti Drugs Q3 FY23 revenue grows 4%

Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY


Dr. Reddy's Laboratories launches Difluprednate Ophthalmic Emulsion 0.05% in US
News | January 28, 2023

Dr. Reddy's Laboratories launches Difluprednate Ophthalmic Emulsion 0.05% in US

The Durezol brand and generic had US sales of approximately US $40 million MAT for the most recent twelve months ending in Nov 2022 according to IQVIA


Dr. Reddys Laboratories Q3 FY2023 consolidated PAT up to Rs. 1243.9 Cr
News | January 27, 2023

Dr. Reddys Laboratories Q3 FY2023 consolidated PAT up to Rs. 1243.9 Cr

The company has reported total income of Rs. 6848.5 crores during the period ended December 31, 2022